Oncimmune Holdings plc develops and commercializes products to diagnose cancer in the United Kingdom, North America, Europe, and internationally.
+ 1 more risk
High growth potential with mediocre balance sheet.
Share Price & News
How has Oncimmune Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OCY's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: OCY underperformed the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: OCY underperformed the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Oncimmune Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Oncimmune Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OCY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OCY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OCY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: OCY is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCY is overvalued based on its PB Ratio (13.5x) compared to the DE Biotechs industry average (3.6x).
How is Oncimmune Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: OCY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OCY's is expected to become profitable in the next 3 years.
Revenue vs Market: OCY's revenue (39.5% per year) is forecast to grow faster than the German market (4.2% per year).
High Growth Revenue: OCY's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OCY is forecast to be unprofitable in 3 years.
How has Oncimmune Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCY is currently unprofitable.
Growing Profit Margin: OCY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OCY is unprofitable, and losses have increased over the past 5 years at a rate of -9.6% per year.
Accelerating Growth: Unable to compare OCY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: OCY has a negative Return on Equity (-438.23%), as it is currently unprofitable.
How is Oncimmune Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: OCY's short term assets (£8.7M) exceed its short term liabilities (£2.2M).
Long Term Liabilities: OCY's short term assets (£8.7M) exceed its long term liabilities (£8.3M).
Debt to Equity History and Analysis
Debt Level: OCY's debt to equity ratio (331.9%) is considered high.
Reducing Debt: OCY had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Inventory Level: OCY has a low level of unsold assets or inventory.
Debt Coverage by Assets: OCY's debt is covered by short term assets (assets are 1.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OCY has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OCY has less than a year of cash runway if free cash flow continues to reduce at historical rates of -24.2% each year
What is Oncimmune Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OCY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OCY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OCY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OCY's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Adam Hill (39yo)
Dr. Adam Mark Hill, MB, PhD, has been the Chief Executive Officer at Oncimmune Holdings Plc since September 2018. Dr. Mark also served as Director at Oncimmune Holdings Plc. He served as Chief Medical Offi ...
CEO Compensation Analysis
Compensation vs Market: Adam's total compensation ($USD320.24K) is about average for companies of similar size in the German market ($USD432.27K).
Compensation vs Earnings: Adam's compensation has been consistent with company performance over the past year.
|CEO & Director||1.5yrs||UK£258.00k||no data|
|Group Chief Financial Officer||1.25yrs||no data||no data|
|Chief Scientific Officer||0.42yr||no data||no data|
|Head of Investor Relations||0.67yr||no data||no data|
|General Counsel & Company Secretary||1.25yrs||no data||no data|
|Chief Medical Officer of US||4.17yrs||no data||no data|
|Chief Commercial Officer of Asia||3.5yrs||no data||no data|
|Senior Vice President of Market Access & Reimbursement Oncimmune (Usa)||2.92yrs||no data||no data|
|Chief Commercial Officer||0.42yr||no data||no data|
Experienced Management: OCY's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|CEO & Director||1.5yrs||UK£258.00k||no data|
|Independent Non-Executive Director||3.75yrs||UK£36.00k||no data|
|Non-Executive Director||no data||no data||4.44% £1.5m|
|Independent Non Executive Director||6.17yrs||UK£18.00k||no data|
|Non-Executive Vice Chairman||1.5yrs||UK£146.00k||5.12% £1.8m|
|Senior Independent Non-Executive Director||no data||UK£36.00k||no data|
|Non Executive Director||4.42yrs||no data||no data|
|Non-Executive Chairman||4.5yrs||UK£75.00k||no data|
|Independent Non-Executive Director||3.42yrs||UK£41.00k||0.014% £4.9k|
|Non-Executive Director||1.5yrs||no data||no data|
Experienced Board: OCY's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OCY insiders have bought and sold the same number of shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.1%.
Oncimmune Holdings plc's company bio, employee growth, exchange listings and data sources
- Name: Oncimmune Holdings plc
- Ticker: OCY
- Exchange: BST
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£30.993m
- Listing Market Cap: UK£34.696m
- Shares outstanding: 63.25m
- Website: https://www.oncimmune.com
Number of Employees
- Oncimmune Holdings plc
- D6 Building
- 1 Thane Road
- NG90 6BH
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ONC||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||May 2016|
|OCY||BST (Boerse-Stuttgart)||Yes||Ordinary Shares||DE||EUR||May 2016|
Oncimmune Holdings plc develops and commercializes products to diagnose cancer in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops EarlyCDT-Liver, a blood test for the early detection of hepatocellular carcinoma in high-risk patients with liver lesions of all sizes; SeroTag, a platform that is used to discover and validate biomarkers and develop precision diagnostic tools from minimally-invasive liquid biopsies; and NavigAID for autoimmune diseases. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/27 23:41|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.